IN2014DN09297A - - Google Patents

Info

Publication number
IN2014DN09297A
IN2014DN09297A IN9297DEN2014A IN2014DN09297A IN 2014DN09297 A IN2014DN09297 A IN 2014DN09297A IN 9297DEN2014 A IN9297DEN2014 A IN 9297DEN2014A IN 2014DN09297 A IN2014DN09297 A IN 2014DN09297A
Authority
IN
India
Prior art keywords
nanoparticles
methods
octylcyanoacrylate
exendin
obesity
Prior art date
Application number
Inventor
Sean Matthew Cleveland
Mark Andrew Paulik
Stefan Salomon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2014DN09297A publication Critical patent/IN2014DN09297A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The disclosure relates to nanoparticles comprising poly(octylcyanoacrylate) for oral administration of a biologically active polypeptide in particular a metabolic peptide such as exendin 4. Also disclosed are methods of producing such nanoparticles pharmaceutical compositions comprising such nanoparticles and methods of treating metabolic disorders such as obesity using such nanoparticles.
IN9297DEN2014 2012-05-16 2013-05-16 IN2014DN09297A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261647633P 2012-05-16 2012-05-16
PCT/IB2013/000964 WO2013171570A1 (en) 2012-05-16 2013-05-16 Polypeptide loaded poca nanoparticles for oral administration

Publications (1)

Publication Number Publication Date
IN2014DN09297A true IN2014DN09297A (en) 2015-07-10

Family

ID=48577784

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9297DEN2014 IN2014DN09297A (en) 2012-05-16 2013-05-16

Country Status (10)

Country Link
US (1) US20150342897A1 (en)
EP (1) EP2849775A1 (en)
JP (1) JP2015523332A (en)
KR (1) KR20150010953A (en)
CN (1) CN104411321A (en)
AU (1) AU2013261214A1 (en)
CA (1) CA2873536A1 (en)
IN (1) IN2014DN09297A (en)
RU (1) RU2014150850A (en)
WO (1) WO2013171570A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104799440B (en) * 2014-01-23 2016-06-08 香港纺织及成衣研发中心有限公司 Improve function clothes and the manufacture method thereof of metabolic syndrome
CN105342999A (en) * 2014-08-18 2016-02-24 山东绿叶制药有限公司 Exenatide oral nanoparticle
CN109675020B (en) * 2019-01-11 2021-05-04 浙江大学 Oral GLP-1 polypeptide nano preparation and preparation method and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3262329B2 (en) 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス GLP-1 analog useful for the treatment of diabetes
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
DK1019077T4 (en) 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc New exendin agonist compounds
EP1032587B2 (en) 1997-11-14 2013-03-13 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
EP1066314B1 (en) 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
WO1999040788A1 (en) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2002226897B2 (en) 2000-12-07 2007-10-25 Eli Lilly And Company GLP-1 fusion proteins
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2500918T3 (en) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Albumin and interferon beta fusion proteins
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
SI2932981T1 (en) 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20110182805A1 (en) 2005-06-17 2011-07-28 Desimone Joseph M Nanoparticle fabrication methods, systems, and materials
US20080138418A1 (en) * 2006-12-07 2008-06-12 Tong Shen Enterprise Co., Ltd. Nanoparticles composed of alkyl-cyanoacrylate polymers
EP3560672A1 (en) 2007-10-12 2019-10-30 Liquidia Technologies, Inc. Method for producing particles

Also Published As

Publication number Publication date
CA2873536A1 (en) 2013-11-21
CN104411321A (en) 2015-03-11
AU2013261214A1 (en) 2014-11-20
JP2015523332A (en) 2015-08-13
KR20150010953A (en) 2015-01-29
EP2849775A1 (en) 2015-03-25
WO2013171570A1 (en) 2013-11-21
US20150342897A1 (en) 2015-12-03
RU2014150850A (en) 2016-07-10

Similar Documents

Publication Publication Date Title
IN2014MN02132A (en)
MX2014015258A (en) Fibroblast growth factor 21 variants.
TN2014000096A1 (en) Fibroblast growth factor 21 variants
IN2014KN02830A (en)
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX2013008851A (en) Compostions and methods for treating chronic inflammation and inflammatory diseases.
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
UA109991C2 (en) CARBAMATE COMPOUNDS, THEIR PREPARATION AND APPLICATION
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
IN2012DN06720A (en)
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
MX2019003619A (en) Bromocriptine formulations.
UA113962C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT
TN2014000046A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
IN2012DN00239A (en)
TN2015000267A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
IN2014DN09297A (en)
IN2014MN02156A (en)
WO2014039074A3 (en) Therapeutic compositions and related methods
IL230751A0 (en) Novel peptides,compositions comprising the same and uses thereof in methods for the treatment of metabolic ,cardiac and immune related disorders
PH12014501352A1 (en) Non-enteric pharmaceutical composition comprising crofelemer
UA112981C2 (en) OPTION OF HUMAN GDNF
WO2013038200A3 (en) Neurodevelopmental disorders